spacer
home > ebr > autumn 2018 > rising to the challenge
PUBLICATIONS
European Biopharmaceutical Review

Rising to the Challenge

Advanced therapy medicinal products (ATMPs) represent one of the fastest-growing areas of clinical research due to their potential to cure severe chronic conditions. Despite the important health benefits that ATMPs are expected to bring, relatively few have reached the market, and several have been subsequently withdrawn. Oncology indications remain the largest sector in the UK, and, while Phase 3 trials have increased, most are still in early phase development. Therefore, it is likely to be several years before the full potential for ATMPs is translated into meaningful patient benefit and will be dependent upon researchers overcoming numerous challenges, including recruitment, operational, and safety considerations. Overcoming these challenges requires innovation, collaboration, and sound strategic development to ensure ATMPs are brought to market efficiently and without a prohibitive impact on drug budgets. This article will discuss how researchers in the UK are at the forefront of this scientific endeavour, with several exciting collaborations, backed by Innovate UK, generating optimism for future success.

The ATMP Market

ATMPs are a new generation of treatments that use gene therapy, cell therapy, and tissue engineering. They offer unprecedented promise for the treatment of diseases or injuries that currently have a high, unmet medical need, such as Alzheimer’s disease, cancer, muscular dystrophy, ophthalmology, and skin in burns victims. Given their curative potential in severe chronic conditions, ATMPs are, unsurprisingly, one of the fastest-growing areas of research, with an estimated global market opportunity of up to £14 billion by 2025, with predicted additional year-on-year growth potential of 25% to 2030.

While optimism may be justified for the future of ATMPs, the situation today is that this technology remains extremely complex and expensive and is only available to a small number of patients. Results from clinical studies have shown promise, but few products have yet to reach the market – only 10 have been approved in Europe, most recently being Alofisel (to treat anal fistulas in Crohn’s Disease) from TiGenix/Takeda. Of these, four have since been withdrawn. This is slow progress considering that the first ATMP, chondrocelect (to repair damage to the cartilage in the knee), was approved nine years ago, especially given the level of interest and investment in the field.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Fiona Thistlethwaite is a Medical Oncology Consultant within the experimental cancer medicine team at The Christie Hospital, UK, and Honorary Senior Lecturer at the Division of Cancer Sciences, Faculty of Biology Medicine & Health, at The University of Manchester, UK. Fiona is also the Director for iMATCH.

Dr Ian Thomas is a drug development expert with several decades of early and late phase oncology experience. In his role as Clinical Delivery Director for Aptus Clinical, a specialist CRO, Ian leads the company’s advanced therapy clinical development activities and is extensively involved in supporting iMATCH.
spacer
Dr Fiona Thistlethwaite
spacer
spacer
spacer
Dr Ian Thomas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Change of Company Name: VTU Technology is now VALIDOGEN

VTU Technology GmbH, a leading, globally acting Austrian biotech contract research company developing microbial strains and processes for the production of recombinant proteins, announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.
More info >>

White Papers

Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?

Clinical Professionals

Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >>

 
Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement